AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31154414
Drug: TCZ mono
RxNorm normalized name: tiotropium bromide mono
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCZ mono (Tocilizumab monotherapy)
Trial: 26666374
Drug: Light-emitting diode
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Light-emitting diode therapy (LEDT) administered with a multidiode cluster probe (50 GaAIA LEDs, 850 ηm, 75 mW each diode, and 3 J per point) before exercise sessions.
Trial: 23257316
Drug: Intralesion injections
RxNorm normalized name: flumethasone
DrugBank: Flumethasone (DB00663)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesion injections of pingyangmycin in combination with triamcinolone acetonide
Trial: 23257316
Drug: Intralesion injections
RxNorm normalized name: flumethasone
DrugBank: Flumethasone (DB00663)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesion injections of pingyangmycin alone
Trial: 21989212
Drug: Minimal acupuncture
RxNorm normalized name: Centipeda minima whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimal acupuncture for two seconds in LI4, administered during six visits to the clinic, twice weekly.
Trial: 12701865
Drug: 5 IU/cc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 IU/cc of low molecular weight heparin (LMWH) in vitrectomy infusion fluid
Trial: 12701865
Drug: No heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No heparin in the infusion fluid (control group)
Trial: 9229416
Drug: Palliative treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palliative treatments
Trial: 3292159
Drug: 3 percent
RxNorm normalized name: SALICYLIC ACID 3 g in 100 g TOPICAL GEL [Keralyt 3 PERCENT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 percent topical minoxidil solution applied twice daily for one year to half the scalp
Trial: 25617224
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D treatment (400,000 IU)
Trial: 23782178
Drug: Clopidogrel (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (0.2 mg/kg/day)
Trial: 21416132
Drug: Fibrinolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrinolytic therapy with streptokinase (SK)
Trial: 18493312
Drug: gatifloxacin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gatifloxacin (10 mg/kg/day)
Trial: 18493312
Drug: azithromycin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: azithromycin (20 mg/kg/day)
Trial: 16790698
Drug: Oral cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cyclophosphamide (≤2 mg/kg/day)
Trial: 9361375
Drug: L-Arginine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Arginine infusion
Trial: 9361375
Drug: Oral L-Arginine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral L-Arginine supplementation
Trial: 1558413
Drug: Bolus intravenous
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus intravenous cimetidine (300 mg every 6 hours)
Trial: 17906160
Drug: Single 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 200 mg dose of pirfenidone
Trial: 17906160
Drug: Single 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 400 mg dose of pirfenidone
Trial: 17906160
Drug: Single 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 600 mg dose of pirfenidone
Trial: 17906160
Drug: Multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of 400 mg pirfenidone administered 3 times daily (tid)
Trial: 16044340
Drug: Capecitabine (1,250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine (1,250 mg/m2 twice daily for 14 days, followed by a 7-day rest period, n=10)
Trial: 16044340
Drug: 5‐FU/LV (Mayo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐FU/LV (Mayo Clinic regimen: LV 20 mg/m2 followed by 5‐FU 425 mg/m2, administered as an i.v. bolus on days 1‐5 every 28 days, n=10)
Trial: 12402370
Drug: Educational program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Educational program focused on coping with residual and relapse warning signs, managing drug side effects, medication compliance, and daily routines; included self-efficacy method, manuals, videotapes, small group discussions, and telephone coaching
Trial: 7781143
Drug: Cimetidine 300
RxNorm normalized name: cimetidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 300 mg i.v. before paclitaxel
Trial: 7781143
Drug: Famotidine 20
RxNorm normalized name: famotidine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine 20 mg i.v. before paclitaxel
Trial: 7273650
Drug: CHOP chemotherapy
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CHOP chemotherapy (stratified for Stage III)
Trial: 29294507
Drug: Intravenous Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Acetaminophen (IVA)
Trial: 26062183
Drug: Three-spasm-needle therapy
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-spasm-needle therapy applied to Jiejian, Xuehaishang and Houxuehai, given once every two days for 20 days, with 3 sessions total.
Trial: 26062183
Drug: Conventional physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional physical therapies (Bobath therapy and lower extremities therapy) and scalp acupuncture (seven‐intelligent needles) in the control group, given once every day for 20 days, with 3 sessions total.
Trial: 21214919
Drug: Self-administered questionnaire
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered questionnaire based on Azjen's Theory of Planned Behaviour
Trial: 11696050
Drug: Ultrasonic nebulizer
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasonic nebulizer with low output of 0.87 mL/min
Trial: 11696050
Drug: Ultrasonic nebulizer
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasonic nebulizer with high output of 1.90 mL/min
Trial: 2897516
Drug: Standard anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard anticoagulant control with rabbit brain thromboplastin (therapeutic range 18‐24 s; INR 2.5‐40)
Trial: 29467523
Drug: Low-dose hydrocortisone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose hydrocortisone (0.5 mg/kg twice per day for 7 days, followed by 0.5 mg/kg per day for 3 days)
Trial: 23552131
Drug: Cardiac Resynchronization
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac Resynchronization Therapy (CRT) + Optimal Medical Therapy (OMT)
Trial: 9103747
Drug: 12-session cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-session cognitive-behavioral treatment (CBT12)
Trial: 9103747
Drug: 4-session computer-assisted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-session computer-assisted cognitive-behavioral treatment (CBT4-CA)
Trial: 8460755
Drug: Propofol and
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol and fentanyl combination
Trial: 27698600
Drug: Sublingual Misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual Misoprostol (400 µg)
Trial: 27698600
Drug: Vaginal Misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vaginal Misoprostol (400 µg)
Trial: 25127240
Drug: Probiotic L.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic L. rhamnosus GR‐1 and L. reuteri RC‐14 (2.5×10^9 CFU each)
Trial: 25127240
Drug: Probiotic L.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic L. rhamnosus GR‐1 and L. reuteri RC‐14
Trial: 15841891
Drug: Education and
RxNorm normalized name: zinc pyrithione Medicated Shampoo [Free and Clear]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Education and an educational pamphlet about the risks of glucocorticoid-induced osteoporosis, monitoring of drug therapy by pharmacists.
Trial: 12459688
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of phenylephrine 50 microg/ml and ephedrine 1.5 mg/ml
Trial: 7661160
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg b.i.d. plus amoxicillin 1 g t.i.d.
Trial: 7661160
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg b.i.d. plus amoxicillin 0.5 g t.i.d.
Trial: 7661160
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg b.i.d. plus amoxicillin 1 g suspension t.i.d. (re-treatment)
Trial: 7661160
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg b.i.d. plus amoxicillin 3 g (side effects)
Trial: 7661160
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg b.i.d. plus amoxicillin 1.5 g (side effects)
Trial: 7064879
Drug: Folic acid,
RxNorm normalized name: folic acid, combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Folic acid, 10 mg daily for 3 months
Trial: 7064879
Drug: Placebo (ascorbic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (ascorbic acid, 10 mg daily for 3 months)
Trial: 31836300
Drug: Intracavernous injection
RxNorm normalized name: Bivalirudin 250 mg INTRACAVERNOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracavernous injection (ICI) alone
Trial: 26934941
Drug: Gradual withdrawal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gradual withdrawal of remifentanil infusion
Trial: 26934941
Drug: Abrupt withdrawal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abrupt withdrawal of remifentanil infusion
Trial: 24611922
Drug: Interviewer-administered method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interviewer-administered method
Trial: 24611922
Drug: Self-administered method
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered method
Trial: 17553467
Drug: Venlafaxine ER
RxNorm normalized name: Venlafaxine ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine ER (titrated from 37.5 mg to a maximum of 225 mg over 16 weeks)
Trial: 15037872
Drug: Candesartan 8-16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan 8-16 mg daily
Trial: 55715
Drug: Oral disodium
RxNorm normalized name: etidronate disodium Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral disodium cromoglycate (2 g/day)
Trial: 30064262
Drug: Daily quadriceps
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily quadriceps exercise at home for 30 minutes (control group)
Trial: 25805451
Drug: Dose delays
RxNorm normalized name: Delayed Release Oral Granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose delays and reductions
Trial: 21375445
Drug: Psychological therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychological therapies (relaxation training, biofeedback, multimodal cognitive-behavioral therapy)
Trial: 21375445
Drug: Hypnosis and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypnosis and acceptance and commitment therapy
Trial: 16330291
Drug: RSG/MET (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RSG/MET (4 mg/2 g per day, escalated to 8 mg/2 g per day)
Trial: 16330291
Drug: MET (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MET (2.5 g/d, escalated to 3 g/d)
Trial: 2737799
Drug: sustained-release capsule
RxNorm normalized name: Dilacor 240mg Sustained-Release Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sustained-release capsule with breakfast
Trial: 2737799
Drug: sustained-release capsule
RxNorm normalized name: Dilacor 240mg Sustained-Release Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sustained-release capsule in fasting state
Trial: 2737799
Drug: tablet form
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet form
Trial: 24099237
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg oral mosapride
Trial: 19783538
Drug: Magnesium sulphate
RxNorm normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium sulphate 30 mg kg(‐1) bolus + 10 mg kg(‐1) h(‐1) continuous infusion (Mg 30 group)
Trial: 19783538
Drug: Magnesium sulphate
RxNorm normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium sulphate 45 mg kg(‐1) bolus + 15 mg kg(‐1) h(‐1) continuous infusion (Mg 45 group)
Trial: 19783538
Drug: Magnesium sulphate
RxNorm normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium sulphate (both Mg 30 and Mg 45 groups)
Trial: 7781139
Drug: Hepsulfam at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepsulfam at 800 mg/m2
Trial: 7781139
Drug: Hepsulfam at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepsulfam at 640 mg/m2
Trial: 7781139
Drug: Hepsulfam at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepsulfam at 480 mg/m2
Trial: 7781139
Drug: Hepsulfam at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepsulfam at doses > or = 640 mg/m2
Trial: 2332564
Drug: Inhaled budesonide
RxNorm normalized name: budesonide Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled budesonide (0.4 mg per day)
Trial: 2332564
Drug: Oral budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral budesonide (1.4 mg per day)
Trial: 7010511
Drug: Intra-articular steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular steroid therapy (20 mg of triamcinalone hexacetonide)
Trial: 31371386
Drug: Weekly retraining
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly retraining (1-month group)
Trial: 26121832
Drug: Composite acoustic
RxNorm normalized name: aconite
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Composite acoustic therapy (personalized) for the first 30 days, followed by music therapy for the next 31-90 days.
Trial: 26121832
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no sound therapy).
Trial: 21457214
Drug: Clobetasol propionate
RxNorm normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Clobetasol propionate 0·05% ointment (n = 30)
Trial: 21457214
Drug: Tacrolimus 0·1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrolimus 0·1% ointment (n = 31)
Trial: 19587362
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of aliskiren and irbesartan
Trial: 7816516
Drug: Both enteral
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both enteral and parenteral feeding
Trial: 29196578
Drug: Quinidine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinidine (300 mg/d)
Trial: 29196578
Drug: Quinidine (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinidine (900 mg/d and 600 mg/d)
Trial: 26603881
Drug: Prebiotic (50%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prebiotic (50% inulin and 50% fructo-oligosaccharide), 6 g twice daily from 1 week before to 3 weeks after RT
Trial: 26603881
Drug: Placebo (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (6 g maltodextrin twice daily from 1 week before to 3 weeks after RT)
Trial: 25464565
Drug: D‐methionine tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D‐methionine tablets
Trial: 22540883
Drug: Exenatide +
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exenatide + metformin
Trial: 27918443
Drug: Olive Leaf
RxNorm normalized name: OLIVE LEAF
DrugBank: Olea europaea leaf (DB14745)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olive Leaf Extract (OLE) 20 mL daily for 8 weeks
Trial: 23962455
Drug: Abatacept (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abatacept (125 mg weekly)
Trial: 23962455
Drug: Adalimumab (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab (40 mg bi-weekly)
Trial: 22648709
Drug: Alginate-based preload
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alginate-based preload supplement (15 g fiber)
Trial: 22648709
Drug: Placebo preload
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo preload supplement
Trial: 20697939
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg twice a day and 20 mg mosapride thrice a day for a total duration of 6 weeks.
Trial: 15941145
Drug: Allicor (Allium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allicor (Allium sativum preparation) for 12 months
Trial: 10577446
Drug: Ecadotril 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ecadotril 50 to 400 mg twice daily
Trial: 1678221
Drug: Histamine (1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histamine (1, 3.3, 10, 33, and 100 micrograms/ml) injected intradermally
Trial: 7055526
Drug: General anaesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anaesthesia with thiopentone, fentanyl and nitrous oxide, infusion of isotonic saline solution 5ml min‐1 (Group I)
Trial: 7055526
Drug: General anaesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anaesthesia with thiopentone, fentanyl and nitrous oxide, infusion of isotonic saline solution 15 ml min‐1 (Group II)
Trial: 29241582
Drug: 10/20‐PRO (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10/20‐PRO (10 g protein followed by 20 g whey protein isolate 120 minutes later)
Trial: 29241582
Drug: 30‐PRO (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30‐PRO (30 g protein breakfast)
Trial: 29241582
Drug: 10‐PRO (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10‐PRO (10 g protein breakfast, control)
Trial: 24307240
Drug: DTaP5 (five-component
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTaP5 (five-component acellular pertussis vaccine)
Trial: 24307240
Drug: DTwP (whole-cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTwP (whole-cell pertussis vaccine)
Trial: 24307240
Drug: DTaP2 (two-component
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTaP2 (two-component acellular pertussis vaccine)
Trial: 24307240
Drug: No vaccine
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No vaccine (1997 seroprevalence study)
Trial: 20214328
Drug: Western medical
RxNorm normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medical routine therapy combined with QQG
Trial: 20214328
Drug: Western medical
RxNorm normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medical routine therapy with placebo
Trial: 15590360
Drug: Simvastatin 20
RxNorm normalized name: simvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 20 mg/day + vitamin C 500 mg/day
Trial: 15590360
Drug: Simvastatin 20
RxNorm normalized name: simvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 20 mg/day + vitamin E 400 IU/day
Trial: 11328193
Drug: Losigamone (3x500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losigamone (3x500 mg/die)
Trial: 3110200
Drug: Dexamethasone (DXM)
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone (DXM) 2.25 mg/day
Trial: 25331194
Drug: Formulations containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulations containing HPC with intrinsic viscosities above 9 dL/g and in quantities above 30%
Trial: 25331194
Drug: Formulations containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulations containing HPMC with intrinsic viscosities above 9 dL/g and in quantities above 30%
Trial: 24780407
Drug: Low-dose subconjunctival
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose subconjunctival cyclosporine A (CsA) implants
Trial: 24780407
Drug: High-dose subconjunctival
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose subconjunctival cyclosporine A (CsA) implants
Trial: 24780407
Drug: Placebo (carrier
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (carrier only) implants
Trial: 9578342
Drug: Antioxidant fortified
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant fortified margarine (15 g/d providing 121 mg vitamin C, 31 mg vitamin E, 2.7 mg alpha‐carotene, and 5.3 mg beta‐carotene)
Trial: 18800453
Drug: Losartan potassium
RxNorm normalized name: Losartan Potassium
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Losartan potassium 50 mg once or twice daily, or 100 mg once daily